CD24 Contributes to Treatment Effect in ABC-DLBCL Patients with R-CHOP Resistance

Li-Yan Qiao,Han-Bing Li,Yue Zhang,Di Shen,Peng Liu,Yi-Qun Che

DOI: https://doi.org/10.2147/PGPM.S310816

2021-05-26

Pharmacogenomics and Personalized Medicine

Abstract:Li-Yan Qiao, 1, * Han-Bing Li, 2, * Yue Zhang, 2 Di Shen, 2 Peng Liu, 3 Yi-Qun Che 2 1 Department of Stomatology, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, People's Republic of China; 2 Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China; 3 Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China *These authors contributed equally to this work Correspondence: Yi-Qun Che Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China Tel/Fax + 86-10-87788746 Email Peng Liu Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China Tel/Fax + 86-10-87788507 Email Purpose: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma and of which the prognosis of activated B-cell-like (ABC) subtype is poor. Although R-CHOP significantly improves the survival of patients with DLBCL, 20% to 40% of patients were resistant to R-CHOP therapy. Thus, screening for candidate therapeutic targets for R-CHOP resistant patients is urgent. The previous researches have shown that CD24 is related to the development, invasion, and metastasis of cancer. Our project aims to clarify the relationship between CD24 and ABC-DLBCL. Patients and Methods: The expression of CD24 mRNA in 118 ABC-DLBCL cases treated with R-CHOP was detected by RNAscope, and the relationship between CD24 expression and R-CHOP treatment response was analyzed. The correlation between CD24 expression and treatment efficiency was further analyzed by data downloaded from the Gene Expression Omnibus (GEO) database. The association between CD24 expression and immune response was conducted using Cell-type Identification By Estimating Relative Subsets Of RNA Transcripts (CIBERSORT) methodology and Gene Ontology (GO) biological process (BP) analysis. Results: The positive expression rate of CD24 mRNA in ABC-DLBCL patients was 38.1% (45/118). Complete Response (CR) rate was significantly higher in patients with CD24 high expression than those with CD24 low expression ( P =0.039; 44.4% vs 26.0%). CR rate was significantly different between CD24 high and low expression groups in the analysis of GEO datasets ( P =0.003; 83.2% vs 58.0%). The CD24 high expression patients had significantly lower proportions of T cells and nonspecific immune cells in the CIBERSORT analysis. In addition, T−helper 2 cell differentiation and monocyte chemotaxis were repressed in CD24 high expression group in the GO BP analysis. Conclusion: CD24 was correlated with better R-CHOP treatment response and tumor immunosuppression in ABC-DLBCL. CD24 may be a promising signal in treatment and prognosis evaluation in ABC-DLBCL patients. Keywords: ABC-DLBCL, CD24, RNA in situ hybridization, treatment response, tumor immunosuppression Diffuse large B-cell lymphoma (DLBCL), an aggressive lymphoma, is the most common form of non-Hodgkin lymphomas (NHL), accounting for approximately 35% of all new NHLs. 1 DLBCL, as a heterogeneous disease, can be divided into germinal center B-cell like (GCB) and activated B-cell like (ABC) subtypes according to cell-of-origin, with about 10–15% of cases being unclassifiable. 2 The ABC DLBCL relied on regulation of BCR-dependent activation of NF-κB and had poorer prognosis following immunochemotherapy. 3 Currently, R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy is the standard treatment for DLBCL. Although first-line treatment of DLBCL is curative for some patients, 20% to 40% of patients still fail to achieve remission or experience relapse. 4 For patients who are unable to receive high-dose chemotherapy and hematopoietic stem-cell transplantation as second-line therapy, the prognosis is inferior. 5 Hence, the identification of effective ABC-DLBCL next line therapeutic targets and biomarkers for t -Abstract Truncated-

pharmacology & pharmacy